explore -WSS

explore

author：hotspot 2025-08-19 06:17:43 - browse：5

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： How generative AI is inspiring dreams of a health data revolution

hotspot

knowledge

WSS

Stem cell treatment guidelines are released by FDA

NIH nominee Bertagnolli will get October confirmation hearing

New CMS data security rules will hurt Medicare, Medicaid research

Humana sues Biden admin over Medicare Advantage audit rule

Trump surgeon general acknowledges mistakes during Covid

Crinetics acromegaly drug succeeds in late

hotspot

explore

knowledge

Dobbs anniversary: the lost opportunity of abortion as health care

Reporting on presidential health from Reagan to Trump and Biden

In age of alternative facts, a scholarly course on calling out crap

WATCH: Why do our ears pop?

Alkermes shareholders re

Listen: Biogen's potential pivot, & Illumina's next chapter

Hepatitis C has a cure — but many Americans still lack access to it

New CMS data security rules will hurt Medicare, Medicaid research

Hepatitis C has a cure — but many Americans still lack access to it

Ethical issues complicate the benefits of medical crowdfunding

hotspot

Weight loss drugs aren’t covered by Obamacare. That may change

Snackable artificial intelligence, expert AI, and the pharma industry

A new drug could help frostbite victims avoid its ravages

In 'major milestone,' FDA approves first cell therapy for solid tumors

Measles policy set amid Florida outbreak alarms vaccine proponents

New CMS data security rules will hurt Medicare, Medicaid research

hotspot

knowledge

hotspot

explore